United Therapeutics IPF Opportunity Outweighs Base Business Risks, UBS Says

MT Newswires Live07-01

United Therapeutics' (UTHR) pursuit of the idiopathic pulmonary fibrosis market is "the more important debate" as the IPF peak opportunity could be about twice the size of the current revenue base, UBS said in a note Monday.

The brokerage said it expects the company to file for Tyvaso in IPF by the end of summer and believes investors looking for a "dip" in the company's valuation on the impact to base business "could be disappointed."

For Q2, UBS expects $823 million in revenue, above the $813 million consensus estimate.

It maintained the company's buy rating and $750 price target.

Price: 541.02, Change: -3.90, Percent Change: -0.72

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2648566139?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-01 02:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2648566139","market":"us","top_or_hot":-1,"title":"United Therapeutics IPF Opportunity Outweighs Base Business Risks, UBS Says","media":"MT Newswires Live","content":"<html><body><p> United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (UTHR) pursuit of the idiopathic pulmonary fibrosis market is \"the more important debate\" as the IPF peak opportunity could be about twice the size of the current revenue base, UBS said in a note Monday.</p><p>The brokerage said it expects the company to file for Tyvaso in IPF by the end of summer and believes investors looking for a \"dip\" in the company's valuation on the impact to base business \"could be disappointed.\"</p><p>For Q2, UBS expects $823 million in revenue, above the $813 million consensus estimate.</p><p>It maintained the company's buy rating and $750 price target.</p><p>Price: 541.02, Change: -3.90, Percent Change: -0.72</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>United Therapeutics IPF Opportunity Outweighs Base Business Risks, UBS Says</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUnited Therapeutics IPF Opportunity Outweighs Base Business Risks, UBS Says\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-07-01 02:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> United <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>' (UTHR) pursuit of the idiopathic pulmonary fibrosis market is \"the more important debate\" as the IPF peak opportunity could be about twice the size of the current revenue base, UBS said in a note Monday.</p><p>The brokerage said it expects the company to file for Tyvaso in IPF by the end of summer and believes investors looking for a \"dip\" in the company's valuation on the impact to base business \"could be disappointed.\"</p><p>For Q2, UBS expects $823 million in revenue, above the $813 million consensus estimate.</p><p>It maintained the company's buy rating and $750 price target.</p><p>Price: 541.02, Change: -3.90, Percent Change: -0.72</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2648566139","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2648566139","pubTimestamp":1782844500,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"United Therapeutics'  pursuit of the idiopathic pulmonary fibrosis market is \"the more important debate\" as the IPF peak opportunity could be about twice the size of the current revenue base, UBS said in a note Monday.The brokerage said it expects the company to file for Tyvaso in IPF by the end of summer and believes investors looking for a \"dip\" in the company's valuation on the impact to base business \"could be disappointed.\"For Q2, UBS expects $823 million in revenue, above the $813 million consensus estimate.It maintained the company's buy rating and $750 price target.Price: 541.02, Change: -3.90, Percent Change: -0.72","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU1571399168.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"IP\" (USD) ACC","LU1699723380.USD":"ALLSPRING GLOBAL LONG/SHORT EQUITY \"AP\" (USD) ACC","UTHR":"美国联合医疗","BK4532":"文艺复兴科技持仓"},"translate_title":"瑞银表示，United Therapeutics IPF机会超过基本业务风险","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"UTHR":1.5},"content_text":"United Therapeutics' (UTHR) pursuit of the idiopathic pulmonary fibrosis market is \"the more important debate\" as the IPF peak opportunity could be about twice the size of the current revenue base, UBS said in a note Monday.The brokerage said it expects the company to file for Tyvaso in IPF by the end of summer and believes investors looking for a \"dip\" in the company's valuation on the impact to base business \"could be disappointed.\"For Q2, UBS expects $823 million in revenue, above the $813 million consensus estimate.It maintained the company's buy rating and $750 price target.Price: 541.02, Change: -3.90, Percent Change: -0.72","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2648566139","isCrawlerRequest":true}